tiprankstipranks
Advertisement
Advertisement

CRBP Stock Latest News

Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial
The FlyCorbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial
5d ago
CRBP
Corbus Pharmaceuticals Appoints CMO Amid Key Trial Launches
PremiumCompany Announcements
Corbus Pharmaceuticals Appoints CMO Amid Key Trial Launches
27d ago
8K
CRBP
Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer
PremiumThe Fly
Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer
27d ago
CRBP
Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho
PremiumThe Fly
Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho
1M ago
CRBP
Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
PremiumThe Fly
Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
2M ago
CRBP
Corbus Pharmaceuticals management to meet with Oppenheimer
PremiumThe FlyCorbus Pharmaceuticals management to meet with Oppenheimer
2M ago
CRBP
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
Premium
The Fly
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
2M ago
CRBP
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
Premium
Ratings
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
2M ago
CRBP
Corbus Pharmaceuticals share selloff overdone, says Guggenheim
PremiumThe Fly
Corbus Pharmaceuticals share selloff overdone, says Guggenheim
2M ago
CRBP
Buy Rating Reiterated on CRB-701’s Best-in-Class Potential and De-Risked Path to Registrational Trial; $40 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on CRB-701’s Best-in-Class Potential and De-Risked Path to Registrational Trial; $40 Price Target Maintained
2M ago
CRBP
Corbus Highlights Promising CRB-701 Data in HPV Cancers
PremiumCompany Announcements
Corbus Highlights Promising CRB-701 Data in HPV Cancers
2M ago
8K
CRBP
Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data
PremiumThe Fly
Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data
2M ago
CRBP
Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho
PremiumThe FlyCorbus Pharmaceuticals price target raised to $44 from $40 at Mizuho
2M ago
CRBP
Corbus Pharmaceuticals Appoints First Chief Business Officer
Premium
Company Announcements
Corbus Pharmaceuticals Appoints First Chief Business Officer
2M ago
8K
CRBP
Corbus Pharmaceuticals names Nishant Saxena as chief business officer
Premium
The Fly
Corbus Pharmaceuticals names Nishant Saxena as chief business officer
2M ago
CRBP
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates
PremiumCompany Announcements
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates
3M ago
8K
CRBP
Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential
PremiumRatings
Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential
3M ago
CRBP
Corbus Pharmaceuticals price target lowered to $54 from $57 at Oppenheimer
PremiumThe Fly
Corbus Pharmaceuticals price target lowered to $54 from $57 at Oppenheimer
3M ago
CRBP
Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies
PremiumThe Fly
Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies
3M ago
CRBP
Corbus Pharmaceuticals reports Q1 EPS ($1.23), consensus ($1.22)
PremiumThe FlyCorbus Pharmaceuticals reports Q1 EPS ($1.23), consensus ($1.22)
3M ago
CRBP
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook
Premium
Company Announcements
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook
3M ago
8K
CRBP
MercadoLibre, T-Mobile, Corbus, Celestica, Elevance Trending With Analysts
Premium
Weekend Updates
MercadoLibre, T-Mobile, Corbus, Celestica, Elevance Trending With Analysts
3M ago
CLS
ELV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >